| Literature DB >> 27746125 |
Juliana Sorraila de Oliveira1, Fátima Husein Abdalla2, Guilherme Lopes Dornelles3, Stephen Adeniyi Adefegha4, Taís Vidal Palma1, Cristiane Signor5, Jamile da Silva Bernardi4, Jucimara Baldissarelli4, Luana Suéling Lenz1, Luana Pereira Magni1, Maribel Antonello Rubin5, Micheli Mainardi Pillat1, Cinthia Melazzo de Andrade6.
Abstract
The present study aimed to investigate the effects of berberine (BRB) on spatial and learning memory, anxiety, acetylcholinesterase activity and cell death in an experimental model of intracerebroventricular streptozotocin (ICV-STZ) induced sporadic Alzheimer's-like dementia. Sixty male Wistar rats were randomly divided into six groups: control (CTR), BRB 50mg/kg (BRB 50), BRB 100mg/kg (BRB 100), streptozotocin (STZ), streptozotocin plus BRB 50mg/kg (STZ+BRB 50), and streptozotocin plus BRB 100mg/kg (STZ+BRB 100). Rats were injected with ICV-STZ (3mg/kg) or saline, and daily oral BRB treatment began on day 4 for a period of 21days. Behavioral tests were carried out on day 17, and rats were euthanized on day 24. Cell death analysis and determination of acetylcholinesterase activity was performed on the cerebral cortex and hippocampus of the brain. Administration of BRB prevented the memory loss, anxiogenic behavior, increased acetylcholinesterase activity and cell death induced by ICV-STZ. This may be explained, in part, by a protective effect of BRB on ameliorating the progression of neurodegenerative diseases, including Alzheimer's disease, and the results of this study provide a better understanding of the effect of BRB on the brain. Thus, BRB may act as a potential neuroprotective agent. Copyright ÂEntities:
Keywords: Alzheimer’s disease; Behavioral tests; Berberine; Cholinergic system; Neuroprotection; Streptozotocin
Mesh:
Substances:
Year: 2016 PMID: 27746125 DOI: 10.1016/j.neuro.2016.10.008
Source DB: PubMed Journal: Neurotoxicology ISSN: 0161-813X Impact factor: 4.294